Stock listing

NASDAQ:CVKD Cadrenal Therapeutics, Inc. Stock

Home listing (NASDAQ) of Cadrenal Therapeutics, Inc.

Follow Cadrenal Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CVKD

$1.70 USD -0.02 (-1.2%)

Close on Nov 20, 2026

Past year -85.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.52 – $1.85 USDNov 20, 2026
Volume
206,569 sharesNov 20, 2026
Market cap
$7.01M USDAt the close on Nov 20, 2026 · price × 4.12M shares outstanding
52-week range
$0.816 – $12.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$770,236 USDMedian day 88,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cadrenal Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CVKD · Home$1.70 USD-0.02 (-1.2%)206,569$1.69$1.85$1.523$1.72Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CVKD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.70-0.02-1.2%$1.69$1.85$1.523206,569
$1.72-0.16-8.5%$1.84$1.84$1.55259,403
$1.88+0.48+34.3%$1.34$1.92$1.34382,569
$1.40-0.11-7.3%$1.49$1.58$1.3874,959
$1.510.000.0%$1.49$1.56$1.4342,092
$1.51+0.06+4.1%$1.41$1.56$1.36184,487
$1.45+0.01+0.7%$1.47$1.48$1.3088,800
$1.44+0.07+5.1%$1.36$1.49$1.278192,200
$1.37+0.39+39.8%$0.98$1.38$0.959374,500
$0.98-0.02-2.0%$1.02$1.09$0.9828,400
$1.00-0.06-5.7%$1.06$1.07$0.9993,700
$1.06-0.07-6.2%$1.10$1.15$1.0543,200
$1.13+0.09+8.7%$1.05$1.14$1.0555,300
$1.04+0.055+5.6%$0.923$1.23$0.923284,800
$0.985+0.042+4.5%$0.94$1.00$0.9480,700
$0.943-0.005-0.5%$0.94$1.00$0.9444,000
$0.948+0.006+0.6%$0.91$0.981$0.9137,500
$0.942+0.032+3.5%$0.90$0.99$0.8660,400
$0.91-0.05-5.2%$0.95$0.96$0.9152,200
$0.96-0.01-1.0%$0.965$1.00$0.9338,200
$0.97-0.05-4.9%$1.03$1.07$0.9619,800
$1.02-0.02-1.9%$1.02$1.03$1.0028,200
$1.04-0.02-1.9%$1.04$1.10$1.0048,700
$1.06-0.03-2.8%$1.06$1.10$0.998152,200
$1.09+0.12+12.4%$0.96$1.12$0.96173,200
$0.97-0.05-4.9%$0.99$1.03$0.965104,200
$1.02+0.023+2.3%$0.93$1.10$0.92344,300
$0.997+0.125+14.3%$0.889$1.06$0.874376,400
$0.872-0.038-4.2%$0.918$0.918$0.816111,400
$0.91-0.02-2.2%$0.974$0.974$0.9082,400
$0.93-0.042-4.3%$0.994$0.994$0.87311,200
$0.972-0.018-1.8%$1.01$1.07$0.9171,781,700
$0.99+0.044+4.7%$0.943$1.05$0.9098,000
$0.946+0.006+0.6%$0.97$1.00$0.93563,000
$0.94-0.03-3.1%$0.98$1.005$0.85149,600
$0.97-0.11-10.2%$1.09$1.09$0.97109,200
$1.08-0.01-0.9%$1.10$1.10$1.0521,700
$1.09-0.03-2.7%$1.10$1.13$1.0838,200
$1.12-0.03-2.6%$1.16$1.16$1.0775,600
$1.15-0.05-4.2%$1.25$1.25$1.13224,700
$1.20-0.12-9.1%$1.31$1.355$1.19119,000
$1.32+0.20+17.9%$1.12$1.348$1.06269,000
$1.12+0.03+2.8%$1.11$1.139$1.0673,500
$1.09+0.02+1.9%$1.07$1.11$1.0666,800
$1.07-0.05-4.5%$1.12$1.16$1.07113,600
$1.12+0.04+3.7%$1.10$1.14$1.0844,900
$1.08+0.03+2.9%$1.05$1.10$1.0155,600
$1.05-0.01-0.9%$1.06$1.12$1.0456,400
$1.06-0.03-2.8%$1.07$1.10$1.05447,600
$1.09-0.09-7.6%$1.17$1.189$1.00228,600
$1.18-0.01-0.8%$1.17$1.20$1.14119,800
$1.19-0.01-0.8%$1.22$1.23$1.14114,600
$1.20-0.02-1.6%$1.20$1.26$1.16161,800
$1.22-0.06-4.7%$1.26$1.295$1.20177,400
$1.28-0.05-3.8%$1.34$1.41$1.27168,600
$1.33-0.18-11.9%$1.40$1.53$1.28388,300
$1.51-0.24-13.7%$1.49$1.58$1.42783,800
$1.75+0.21+13.6%$1.64$2.29$1.4621,599,200
$1.54-0.025-1.6%$1.56$1.60$1.5031,100
$1.565+0.015+1.0%$1.52$1.622$1.5248,200
$1.55+0.02+1.3%$1.56$1.643$1.4924,700
$1.53-0.04-2.5%$1.56$1.61$1.5039,200
$1.57-0.04-2.5%$1.69$1.69$1.5436,200
$1.61+0.02+1.3%$1.62$1.62$1.54136,200
$1.59-0.05-3.0%$1.65$1.725$1.5860,000

Splits

1 split · NASDAQ:CVKD · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
Ticker
NASDAQ:CVKD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Cadrenal Therapeutics, Inc. news

Cadrenal Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 92 in all · newest Oct 7, 2026 · oldest 2023
Decks
14 decks · latest September 2026

Where Cadrenal Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CVKD · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CVKDBOATSUnited StatesUSD

Valuation

Price/book 2.4× against a median of 2.8×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$3.95M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.60

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cadrenal Therapeutics, Inc. · NASDAQ:CVKDUS$7.01MUS$3.95Mn/an/an/a2.4×n/a0.0×1.60
Ascelia Pharma AB · OMXSTO:ACEUS$7.30MUS$3.63Mn/an/an/a0.8×n/a0.0×n/a
AEON Biopharma, Inc. · AMEX:AEONUS$7.27M−US$4.15Mn/an/an/a3.0×n/a0.0×1.04
Pila Pharma AB · OMXSTO:PILAUS$7.01MUS$6.70Mn/an/an/a4.5×n/a0.0×n/a
Ensysce Biosciences, Inc. · NASDAQ:ENSCUS$7.00M−US$22.51Mn/a−3.6×n/a0.3×n/a0.0×1.28
Arctic Bioscience AS · OSL:ABSUS$7.00MUS$11.38Mn/a2.8×n/a0.4×−102.3%0.3×n/a
Alaunos Therapeutics, Inc. · NASDAQ:TCRTUS$6.99MUS$6.37Mn/a2,124×n/a7.2×n/a0.0×0.90
Curanex Pharmaceuticals Inc · NASDAQ:CURXUS$6.92MUS$5.88Mn/an/an/a2.7×n/a0.2×0.84
Cambium Bio Ltd · ASX:CMBUS$6.82MUS$6.18Mn/a14.6×n/a4.3×−638.4%0.1×n/a
MetaVia Inc. · NASDAQ:MTVAUS$6.81M−US$1.97Mn/an/an/a2.8×n/a0.0×1.22
Aligos Therapeutics, Inc. · NASDAQ:ALGSUS$6.64M−US$12.55Mn/a−2.1×n/a0.6×n/a1.1×1.63
Median of the othersUS$6.99MUS$4.75M2.8×2.8×−370.4%0.0×1.13

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
14.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.92 · 2 analysts

Team and board

Officers

OfficerRole
Quang PhamChairman & Chief Executive Officer
John P. SharpInterim Chief Financial Officer
Jeff ColeChief Operating Officer

Board

DirectorRole
Quang PhamChairman & Chief Executive Officer
Glynn WilsonBoard Member
John R. MurphyBoard Member
Lee GoldenBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close+34.3%
Q2 2026Aug 13, 2026 · After close+0.5%
Q1 2026May 7, 2026 · Before open−2.4%
Q3 2025Nov 10, 2025 · Before open−3.2%
Q2 2025Aug 11, 2025 · Before open−1.9%
Q1 2025May 8, 2025 · After close−6.8%
Q4 2024Mar 13, 2025+8.0%
Q3 2024Nov 7, 2024 · After close+8.9%
Q2 2024Aug 7, 2024 · After close+4.7%
Q1 2024May 9, 2024 · Before open−1.1%
All 15 quarters
QuarterResultsShare move
Q4 2023Mar 11, 2024 · Before open−2.8%
Q3 2023Nov 11, 2023 · After close−2.9%
Q2 2023Aug 30, 2023+8.4%
Q4 2022Mar 30, 2023+9.3%
Q2 2022Sep 22, 2022

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck21 slidesSeptember 2026
Investor Presentation (May 2026)Investor deck18 slidesMay 2026
Investor Presentation (December 2025)Investor deck23 slidesDec 11, 2025
Investor Presentation (September 2025)Investor deck26 slidesSep 15, 2025
Investor Presentation (September 2024)Investor deck34 slidesSep 25, 2024
Investor Presentation (September 2024)Investor deck34 slidesSeptember 2024
Investor Presentation (August 2024)Investor deck27 slidesAugust 2024
Investor Presentation (July 2024)Investor deck31 slidesJul 30, 2024
Investor Presentation (May 2024)Investor deck29 slidesMay 2024
Investor Presentation (March 2024)Investor deck37 slidesMar 11, 2024
All 14 decks
DeckKindSlidesDate
Investor Presentation (December 2023)Investor deck37 slidesDecember 2023
Investor Presentation (August 2023)Investor deck36 slidesAugust 2023
Investor Presentation (May 2023)Investor deck32 slidesMay 2023
Investor Presentation (March 2023)Investor deck32 slidesMarch 2023

Open Decks

IPO

Priced at US$5.00 a share on Jan 19, 2023.

Price
US$5.00 a share
Shares offered
3,104,783 shares of common stock · 1,400,000 from the company and 1,704,783 from selling shareholders
Offering size
US$7 million
Underwriters' option
Up to 210,000 more shares
Listing
CVKD on the Nasdaq Capital Market
Underwriters
Boustead Securities, LLC, Sutter Securities, Inc., Revere Securities LLC · In the order on the cover
Shares delivered
On or about Jan 24, 2023

Steps

StepWhen
Draft sent to the SEC in confidenceJul 15, 2022
Filed publiclySep 22, 2022
Amended 6 timesNewest Jan 17, 2023
Shares registered with an exchangeJan 17, 2023
Declared effective by the SECJan 19, 2023
Final prospectus, with the priceJan 23, 2023

Open IPO · From the cover of the final prospectus (424B4) filed Jan 23, 2023

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2008
Revenue000
Cost of revenue1.88K220.1K1.27K220.1K
Gross profit-1.88K-1.98K-1.27K
Research and development4.10M4.21M4.08M392.9K200.0K
Selling, general and administrative9.35M6.75M3.55M
Operating income-13.5M-11.0M-7.63M-2.70M
Depreciation and amortization6.87K1.88K1.98K1.27K
EBITDA-13.5M-11.0M-7.63M-2.70M
Interest expense03.53K107.1K
Income before tax-13.2M-10.7M-8.36M-6.71M
Income tax-165.9K4
Net income-13.2M-10.7M-8.36M-6.71M
Earnings per share, basic-6.64-8.73-9.29-8.66
Earnings per share, diluted-6.64-8.73-9.29

Balance sheet

LineFY2025FY2024FY2023FY2022FY2008
Cash and equivalents4.01M10.0M8.40M32.6K
Receivables5.10K38.2K37.2K
Current assets4.32M10.1M8.49M727.6K
Property, plant and equipment5.17K6.94K2.29K44.6K
Total assets4.33M10.1M8.52M778.2K
Accounts payable650.7K1.50M167.3K404.9K
Current liabilities1.59M2.68M826.9K1.33M
Long-term debt553.3K
Total debt21.4K640.7K
Total liabilities1.59M2.68M826.9K6.33M
Shareholders' equity2.74M7.44M7.69M-5.55M
Shares outstanding2.34M1.78M868.2K775.6K11.7M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-12.6M-7.36M-3.53M-1.31M
Capital spending-5.10K-6.54K-3.25K-2.49K
Free cash flow-12.6M-7.36M-3.53M-1.32M
Cash from investing-5.10K-6.54K-3.25K-2.49K
Cash from financing6.60M8.98M11.9M1.35M
Share buybacks-291.9K0
Change in cash-6.01M1.62M8.37M32.6K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 17, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
S-8 · Registration statement for employee plansOct 8, 2026Offer documentSEC
8-K · Current reportOct 7, 2026Current reportSEC
8-K · Current reportSep 29, 2026Management or board changeSEC
Show 200 filings
FilingDateTypeFiled with
S-8 · Registration statement for employee plansSep 3, 2026Offer documentSEC
8-K · Current reportAug 31, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialAug 3, 2026Meeting noticeSEC
ARS · Annual report to shareholdersAug 3, 2026Annual reportSEC
DEF 14A · Proxy statementAug 3, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 23, 2026Meeting noticeSEC
8-K · Current reportJul 21, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJul 21, 2026Other filingsSEC
424B3 · ProspectusJul 20, 2026Offer documentSEC
8-K · Current reportJul 17, 2026Management or board changeSEC
DJul 15, 2026Other filingsSEC
S-3 · Registration statementJul 13, 2026Offer documentSEC
8-K · Current reportJul 10, 2026Management or board changeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
8-K · Current reportJul 1, 2026Material contractSEC
8-K · Current reportJun 29, 2026Management or board changeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026Current reportSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
8-K · Current reportJun 3, 2026Management or board changeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportApr 30, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveApr 30, 2026Other filingsSEC
424B3 · ProspectusApr 29, 2026Offer documentSEC
CORRESP · Letter to the SECApr 27, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 27, 2026Other filingsSEC
S-3 · Registration statementApr 20, 2026Offer documentSEC
DApr 6, 2026Other filingsSEC
8-K · Current reportApr 1, 2026Material contractSEC
424B5 · ProspectusApr 1, 2026Offer documentSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
8-K · Current reportMar 12, 2026Current reportSEC
8-K · Current reportFeb 24, 2026Current reportSEC
424B3 · ProspectusJan 2, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 2, 2026Other filingsSEC
DDec 31, 2025Other filingsSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
UPLOAD · Letter from the SECDec 31, 2025Other filingsSEC
CORRESP · Letter to the SECDec 30, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
S-1 · Registration statementDec 23, 2025Offer documentSEC
8-K · Current reportDec 23, 2025Current reportSEC
424B5 · ProspectusDec 23, 2025Offer documentSEC
8-K · Current reportDec 16, 2025Material contractSEC
424B5 · ProspectusDec 16, 2025Offer documentSEC
424B5 · ProspectusDec 16, 2025Offer documentSEC
8-K · Current reportDec 11, 2025Material contractSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 3, 2025Insider tradeSEC
8-K · Current reportDec 1, 2025Management or board changeSEC
8-K · Current reportNov 18, 2025Current reportSEC
424B5 · ProspectusNov 18, 2025Offer documentSEC
8-K · Current reportNov 10, 2025ResultsSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
144 · Notice of proposed saleOct 27, 2025Other filingsSEC
144 · Notice of proposed saleOct 27, 2025Other filingsSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
144 · Notice of proposed saleOct 14, 2025Other filingsSEC
144 · Notice of proposed saleOct 14, 2025Other filingsSEC
144 · Notice of proposed saleOct 9, 2025Other filingsSEC
144 · Notice of proposed saleOct 9, 2025Other filingsSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
144 · Notice of proposed saleOct 6, 2025Other filingsSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
144 · Notice of proposed saleSep 29, 2025Other filingsSEC
144 · Notice of proposed saleSep 29, 2025Other filingsSEC
144/A · Notice of proposed sale, amendedSep 29, 2025Other filingsSEC
4 · Change in ownershipSep 26, 2025Insider tradeSEC
4 · Change in ownershipSep 26, 2025Insider tradeSEC
144 · Notice of proposed saleSep 25, 2025Other filingsSEC
144 · Notice of proposed saleSep 25, 2025Other filingsSEC
144 · Notice of proposed saleSep 24, 2025Other filingsSEC
144 · Notice of proposed saleSep 24, 2025Other filingsSEC
8-K · Current reportSep 24, 2025Meeting outcomeSEC
8-K · Current reportSep 15, 2025Material contractSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
144 · Notice of proposed saleAug 28, 2025Other filingsSEC
144 · Notice of proposed saleAug 28, 2025Other filingsSEC
144 · Notice of proposed saleAug 27, 2025Other filingsSEC
144/A · Notice of proposed sale, amendedAug 27, 2025Other filingsSEC
144 · Notice of proposed saleAug 27, 2025Other filingsSEC
8-K · Current reportAug 11, 2025ResultsSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025Current reportSEC
ARS · Annual report to shareholdersJul 31, 2025Annual reportSEC
DEFA14A · Additional proxy materialJul 31, 2025Meeting noticeSEC
DEF 14A · Proxy statementJul 31, 2025Meeting noticeSEC
8-K · Current reportJul 18, 2025Management or board changeSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportApr 17, 2025Current reportSEC
424B5 · ProspectusApr 17, 2025Offer documentSEC
4/A · Change in ownership, amendedMar 24, 2025Insider tradeSEC
8-K · Current reportMar 13, 2025ResultsSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 4, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
8-K · Current reportFeb 7, 2025Management or board changeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 6, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 3, 2025Offer documentSEC
SCHEDULE 13D · Big-stake noticeJan 29, 2025Big-stake noticeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 15, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansDec 23, 2024Offer documentSEC
424B5 · ProspectusDec 20, 2024Offer documentSEC
424B3 · ProspectusNov 25, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 25, 2024Other filingsSEC
CORRESP · Letter to the SECNov 21, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 20, 2024Other filingsSEC
S-3 · Registration statementNov 14, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
DNov 14, 2024Other filingsSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
8-K · Current reportNov 4, 2024Material contractSEC
424B5 · ProspectusNov 4, 2024Offer documentSEC
8-K · Current reportOct 24, 2024Current reportSEC
SC 13G · Big-stake noticeOct 4, 2024Big-stake noticeSEC
8-K · Current reportSep 25, 2024Current reportSEC
8-K · Current reportSep 5, 2024Current reportSEC
8-K · Current reportAug 20, 2024Current reportSEC
8-K · Current reportAug 16, 2024Current reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024Current reportSEC
8-K · Current reportJul 31, 2024Management or board changeSEC
DEFA14A · Additional proxy materialJun 12, 2024Meeting noticeSEC
ARS · Annual report to shareholdersJun 11, 2024Annual reportSEC
DEF 14A · Proxy statementJun 11, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementMay 29, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024Current reportSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
8-K · Current reportApr 9, 2024Current reportSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 3, 2024Other filingsSEC
POS AM · Amendment to an effective registrationApr 1, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 21, 2024Other filingsSEC
CORRESP · Letter to the SECMar 18, 2024Other filingsSEC
UPLOAD · Letter from the SECMar 15, 2024Other filingsSEC
S-8 · Registration statement for employee plansMar 12, 2024Offer documentSEC
S-3 · Registration statementMar 12, 2024Offer documentSEC
8-K · Current reportMar 11, 2024Material contractSEC
8-K · Current reportMar 11, 2024ResultsSEC
10-K · Annual reportMar 8, 2024Annual reportSEC
8-K · Current reportMar 5, 2024Current reportSEC
8-K/A · Current report, amendedFeb 15, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 12, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
8-K · Current reportFeb 12, 2024Management or board changeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC

This page holds 200 of 279 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cadrenal Therapeutics, Inc.’s releases · as of Nov 16, 2026

Common shares
4,122,081
Fully diluted
4,122,081

Fully diluted

LineSharesAs of
Common shares4,122,081Nov 16, 2026

Share count over time

CountShares
Nov 16, 20264,122,081

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Hrt Financial LP35,3750.86%US$38,000Sep 30, 2026
Vanguard25,1700.61%US$27,184Sep 30, 2026
Courier Capital LLC19,8370.48%US$21,424Sep 30, 2026
Vectors Research Management, LLC19,8370.48%US$21,424Sep 30, 2026
Geode Capital18,9580.46%US$20,474Sep 30, 2026
Jane Street13,7210.33%US$14,819Sep 30, 2026
Squarepoint Ops LLC12,3630.30%US$13,352Sep 30, 2026
XTX Topco Ltd10,1030.25%US$10,911Sep 30, 2026
Nuveen7,2400.18%US$7,892Sep 30, 2026
UBS5,8610.14%US$6,330Sep 30, 2026
All 22 holders
HolderSharesOf the companyValueAs of
Tower Research Capital LLC (TRC)4,6260.11%US$4,996Sep 30, 2026
Barclays3,8860.09%US$4,197Sep 30, 2026
Grove Bank & Trust1,0000.02%US$1,080Sep 30, 2026
Morgan Stanley7040.02%US$760Sep 30, 2026
Quest 10 Wealth Builders, Inc.380<0.01%US$410Sep 30, 2026
Osaic Holdings, Inc.300<0.01%US$324Sep 30, 2026
Jones Financial Companies Lllp200<0.01%US$230Sep 30, 2026
Rockefeller Capital Management L.P.150<0.01%US$162Sep 30, 2026
BFC Planning, Inc.100<0.01%US$108Sep 30, 2026
Wells Fargo99<0.01%US$107Sep 30, 2026
Archer Investment Corp35<0.01%US$38Sep 30, 2026
IFP Advisors, Inc30<0.01%US$32Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund33,2780.81%US$111KJun 30, 2026
Vanguard Extended Market Index Fund16,8590.41%US$56,309Jun 30, 2026
Fidelity Extended Market Index Fund12,3070.30%US$60,427May 31, 2026
Fidelity Series Total Market Index Fund2,4490.06%US$12,025May 31, 2026
Fidelity Nasdaq Composite Index Fund2,0410.05%US$10,021May 31, 2026
Fidelity Total Market Index Fund1,1090.03%US$5,445May 31, 2026
Dimensional US Sustainability Core 1 ETF9140.02%US$1,837Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Pham Quang X
Director, Officer: Chairman and CEO, 10% owner
Sale7,400USD 3.03US$22,422Jun 29, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale9,029USD 3.05US$27,538Jun 26, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale2,127USD 3.00US$6,381Jun 25, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale2,277USD 3.20US$7,286Jun 23, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale9,167USD 3.55US$32,543Jun 22, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale513USD 3.16US$1,621Jun 17, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale3,613USD 3.18US$11,489Jun 16, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale3,666USD 3.58US$13,124Jun 15, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale12,996USD 3.94US$51,204Jun 12, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale1,462USD 4.12US$6,023Jun 11, 2026
All 22 trades
TradeTradeSharesPriceValueDate
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale3,500USD 4.21US$14,735Jun 10, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale12,992USD 4.06US$52,748Jun 9, 2026
Pham Quang X
Director, Officer: Chairman, CEO and Interim CFO, 10% owner
Sale5,893USD 4.38US$25,811Jun 8, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale2,064USD 4.42US$9,123Jun 5, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale3,898USD 4.41US$17,190Jun 4, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale2,323USD 4.26US$9,896Jun 3, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale349USD 4.46US$1,557Jun 2, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale303USD 5.01US$1,518May 29, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale2,989USD 4.93US$14,736May 28, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale1,165USD 5.69US$6,629May 22, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale3,298USD 5.28US$17,413May 12, 2026
Pham Quang X
Director, Officer: CEO and Chairman, 10% owner
Sale6,476USD 5.76US$37,302May 11, 2026

Big stakes

StakeStakeSharesDateFiling
Quang X. Pham23.60%421KJan 23, 2025Schedule 13D
PNC Financial Services Group, Inc.8.13%233KJun 30, 2026Schedule 13G
Baggett Benjamin Matthew Wall7.30%300KNov 16, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Matthew K Szot
Other companies: INVO Fertility, Inc. (Director · Since at least Sep 13, 2020); SenesTech, Inc. (Director · Since at least Dec 18, 2017); Beeline Holdings, Inc. (Director · Jun 18, 2018 – Jun 30, 2019 · Past); S&W Seed Company (EVP Finance & Admin and CFO · Oct 1, 2017 – Oct 5, 2021 · Past)
Chief Financial Officer · Since at least Jan 19, 2023
John R. Murphy
Other companies: O'Reilly Automotive, Inc. (Director · Since at least May 13, 2022); Summit Materials Inc (Director · Feb 22, 2023 – Sep 29, 2023 · Past)
Board Member · Since at least Jan 19, 2023
Lee Golden
Other companies: PTC Therapeutics, Inc. (EVP & CHIEF MEDICAL OFFICER · Since at least Jun 6, 2023); MetaVia Inc. (Chief Medical Officer · Oct 5, 2016 – Jan 28, 2018 · Past)
Board Member · Since at least Nov 24, 2025
Robert Lisicki
Other companies: Zura Bio Limited (Chief Executive Officer, Director · Jan 8, 2024 – Feb 27, 2025 · Past); Arena Pharmaceuticals Inc (EVP, Chief Commercial Officer · Aug 4, 2020 – Mar 11, 2022 · Past)
Director · Jul 23, 2023 – Jan 23, 2025 · Past
Glynn WilsonBoard Member · Since at least Nov 5, 2026
James J. FergusonChief Medical Officer · May 8, 2025 – Nov 5, 2026 · Past
Jeff ColeChief Operating Officer · Since at least Mar 13, 2025
John P. SharpInterim Chief Financial Officer · Since at least Nov 5, 2026
Quang PhamChairman & Chief Executive Officer · Since at least Jul 1, 2026

Open People

Log in to ask 6ix AI your own questions about Cadrenal Therapeutics, Inc.